secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2023-05-02T23:59:59+00:00
Accession:  0001193125-23-132565
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta to present CABA-201 preclinical data and DSG3-CAART update at ASGCT
-----------------------------------------------------------------------------

- Oral presentation on CD19 CAR T for SLE by CSO Samik Basu at ASGCT on May 16.
- New preclinical data for CABA-201 (CD19 CAR T) shows comparable activity to FMC63 construct.
- Updated DSG3-CAART clinical data shows enhanced persistence with IVIG/cyclophosphamide preconditioning.
- Poster presentations on May 18 and 19; abstracts published on ASGCT website.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000119312523132565/0001193125-23-132565-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000119312523132565/d134990d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-132565

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer